Compulsory licences now available for export of patented pharmaceuticals

  As of 25 August 2015, it is now possible for third parties to apply to the Federal Court of Australia for a compulsory licence to manufacture generic versions of patented pharmaceutical inventions (“PPI”) for export to developing countries to address public health problems.   Background Australia is a signatory to the World Trade Organization

Differences in trans-Tasman patent law: extension of term for pharmaceuticals

This is the latest in a series of articles intended to highlight some of the major differences between the patent laws of Australia and New Zealand. Whereas patentees are typically encouraged to view Australia and New Zealand as a common market, the reality is that this impression may not be 100% accurate. As may be